Last week's twist in the patent fight between Cubist Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. brought renewed attention to the worth of the case advanced by the latter, but it's not clear how the outcome of the battle would affect the ultimate fate of Cubist, which some bankers say is all but assured a takeover, and the only question is price. Read More
